NO942851D0 - - Google Patents

Info

Publication number
NO942851D0
NO942851D0 NO942851A NO942851A NO942851D0 NO 942851 D0 NO942851 D0 NO 942851D0 NO 942851 A NO942851 A NO 942851A NO 942851 A NO942851 A NO 942851A NO 942851 D0 NO942851 D0 NO 942851D0
Authority
NO
Norway
Prior art keywords
cells
polypeptides
receptor
cell types
polypeptide
Prior art date
Application number
NO942851A
Other languages
English (en)
Norwegian (no)
Other versions
NO942851L (no
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO942851D0 publication Critical patent/NO942851D0/no
Publication of NO942851L publication Critical patent/NO942851L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Holo Graphy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO942851A 1992-05-26 1994-08-01 Nytt cytokin som binder CD30 NO942851L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US88971792A 1992-05-26 1992-05-26
US89245992A 1992-06-02 1992-06-02
US89966092A 1992-06-15 1992-06-15
US90722492A 1992-07-01 1992-07-01
US96677592A 1992-10-27 1992-10-27
PCT/US1993/004926 WO1993024135A1 (en) 1992-05-26 1993-05-25 Novel cytokine that binds cd30

Publications (2)

Publication Number Publication Date
NO942851D0 true NO942851D0 (es) 1994-08-01
NO942851L NO942851L (no) 1994-08-01

Family

ID=27542285

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942851A NO942851L (no) 1992-05-26 1994-08-01 Nytt cytokin som binder CD30

Country Status (10)

Country Link
US (7) US5480981A (es)
EP (1) EP0615451B1 (es)
AT (1) ATE311895T1 (es)
AU (2) AU666388B2 (es)
CA (1) CA2131003A1 (es)
DE (1) DE69334070T2 (es)
DK (1) DK0615451T3 (es)
ES (1) ES2252732T3 (es)
NO (1) NO942851L (es)
WO (1) WO1993024135A1 (es)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844119A (en) * 1988-11-21 1989-07-04 Allied-Signal Inc. Integrated three-way and isolation solenoid valve
ES2252732T3 (es) * 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
ES2221717T3 (es) * 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
EP1053316A1 (de) * 1998-02-06 2000-11-22 AbGen GmbH Nukleinsäuren zur modulation zellulärer aktivierung
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US7001999B1 (en) 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
RU2229305C2 (ru) * 1998-04-15 2004-05-27 Лексиген Фармасьютикэлс Корпорейшн Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора ангиогенеза
AU3560399A (en) * 1998-04-15 1999-11-01 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6245525B1 (en) 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
PT2319928E (pt) * 1998-10-23 2013-06-28 Kirin Amgen Inc Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
MXPA01011845A (es) * 1999-05-19 2002-06-21 Lexigen Pharm Corp Expresion y exportacion de proteinas de interferon-alfa como proteinas de fusion fc.
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CN1345246A (zh) * 1999-09-03 2002-04-17 安姆根有限公司 预防或治疗癌症及与癌症相关的骨损失的组合物和方法
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
ATE385517T1 (de) * 1999-12-08 2008-02-15 Amgen Inc Interferon ähnliche moleküle, und deren verwendungen
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
ES2254408T4 (es) * 2000-04-25 2007-10-01 Immunex Corporation Procedimiento de tratamiento de tumores usando terapia fotodinamica.
WO2001083525A2 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
AU7172901A (en) * 2000-06-29 2002-01-14 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US6652854B2 (en) 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US9539348B2 (en) * 2000-08-18 2017-01-10 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
JP4744062B2 (ja) * 2000-10-18 2011-08-10 アメリカ合衆国 生殖能力に不可欠なヒト遺伝子
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
WO2002055694A2 (en) * 2001-01-16 2002-07-18 Genset Sa Discriminative nucleic acid analysis using clone sequence signatures
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
RU2306320C9 (ru) * 2001-05-03 2008-01-27 Мерк Патент Гмбх Рекомбинантное опухолеспецифичное антитело (варианты) и его применение
CN1518459A (zh) * 2001-06-22 2004-08-04 ��һ��������ҩ��ʽ���� 嗜酸性粒细胞疾病的治疗剂
WO2003009863A1 (en) * 2001-07-26 2003-02-06 Genset S.A. Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
RU2312677C9 (ru) * 2001-12-04 2008-03-27 Мерк Патент Гмбх Иммуноцитокины с модулированной селективностью
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
KR100829283B1 (ko) * 2002-01-09 2008-05-13 메다렉스, 인코포레이티드 Ｃｄ３０에 대한 인간 모노클로날 항체
CA2496795C (en) 2002-08-28 2014-06-03 Paul B. Burton Compositions and methods for treating cardiovascular disease
DK1572748T3 (da) * 2002-12-17 2010-08-23 Merck Patent Gmbh Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
AU2004238263A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP2298347B1 (en) * 2003-05-06 2015-09-30 Biogen Hemophilia Inc. Clotting factor chimeric proteins for treatment of a hemostatic disorder
US20050009110A1 (en) * 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
CN100467488C (zh) * 2003-12-30 2009-03-11 默克专利有限公司 Il-7融合蛋白
KR20060124656A (ko) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
US8420087B2 (en) * 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
US7601516B2 (en) * 2004-01-28 2009-10-13 Syntomix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility
EP1737479B1 (en) 2004-02-12 2014-12-17 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Therapeutic administration of the scrambled anti-angiogenic peptide C16Y
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
WO2006010057A2 (en) * 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
ES2381557T3 (es) 2004-08-03 2012-05-29 Innate Pharma Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
CN101103045B (zh) 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
CN101056655A (zh) * 2004-10-01 2007-10-17 米德列斯公司 治疗cd30阳性淋巴瘤的方法
JP4937132B2 (ja) * 2004-12-09 2012-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫原性の低下したｉｌ−７変種
WO2006089232A2 (en) 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against cd30 lacking fucosyl residues
US20090214544A1 (en) * 2005-04-25 2009-08-27 Medarex Method of treating cd30 positive lymphomas
JP2008544246A (ja) * 2005-06-17 2008-12-04 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 正確な磁気バイオセンサー
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
TW200722436A (en) * 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
ES2396569T3 (es) * 2006-01-17 2013-02-22 Medarex, Inc. Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo y xilosilo
EP1986677A2 (en) * 2006-01-25 2008-11-05 Amgen Inc. Thrombopoietic compounds
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2421896A1 (en) * 2009-04-22 2012-02-29 Merck Patent GmbH Antibody fusion proteins with modified fcrn binding sites
WO2011020047A1 (en) 2009-08-14 2011-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of il-15 to increase thymic output and to treat lymphopenia
MX356527B (es) 2010-07-09 2018-06-01 Bioverativ Therapeutics Inc Polipeptidos de factor ix y metodos para usarlos.
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
AU2012286048A1 (en) 2011-07-18 2014-02-20 Arts Biologics A/S Long acting luteinizing hormone (LH) compound
EP2744828A4 (en) 2011-08-16 2014-12-31 Univ Emory JAML-SPECIFIC BINDING AGENTS, ANTIBODIES AND USES THEREOF
WO2013052456A1 (en) 2011-10-05 2013-04-11 Nanosys, Inc. Silicon nanostructure active materials for lithium ion batteries and processes, compositions, components, and devices related thereto
US9360414B2 (en) * 2011-10-14 2016-06-07 University of Pittsburgh—of the Commonwealth System of Higher Education Light refraction imaging to measure liquid volume
CN114748605A (zh) 2011-11-29 2022-07-15 普罗克拉拉生物科学股份有限公司 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途
CN108324943B (zh) * 2012-02-10 2024-03-08 思进股份有限公司 Cd30+癌症的检测和治疗
EP3431492B1 (en) * 2012-04-27 2020-12-23 Novo Nordisk A/S Human cd30 ligand antigen binding proteins
WO2013167750A2 (en) 2012-05-11 2013-11-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
GB201216649D0 (en) * 2012-09-18 2012-10-31 Univ Birmingham Agents and methods
SI2906235T1 (sl) 2012-10-02 2017-12-29 Proclara Biosciences, Inc. Uporaba P3 bakteriofagnih fuzijskih proteinov kot amiloidnih vezavnih sredstev
CN103509121B (zh) 2012-11-22 2015-01-28 苏州康宁杰瑞生物科技有限公司 一种fsh融合蛋白及其制备方法和用途
WO2014093698A1 (en) 2012-12-12 2014-06-19 The Methodist Hospital Research Institute Multi-aptamer-based, cell-specific, one-step tumor cell detection assays
TWI788044B (zh) 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
SG11201509647WA (en) 2013-05-28 2015-12-30 Neurophage Pharmaceuticals Inc Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
AU2015358504A1 (en) 2014-12-03 2017-06-29 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
LT3303373T (lt) 2015-05-30 2020-07-10 Molecular Templates, Inc. Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
SG11201803211TA (en) 2015-11-03 2018-05-30 Ambrx Inc Anti-cd3-folate conjugates and their uses
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
IT201700084299A1 (it) 2017-07-24 2019-01-24 Univ Degli Studi Padova Peptidi derivati dal GAP24 per l’uso nel trattamento della forma X della neuropatia periferica di Charcot-Marie-Tooth
EP3813726A1 (en) * 2018-06-27 2021-05-05 Cirlo GmbH Implants for recruiting and removing circulating tumor cells
EP4294840A1 (en) * 2021-02-17 2023-12-27 Prometheus Biosciences, Inc. Anti-cd30l antibodies and uses thereof
WO2023173084A1 (en) 2022-03-11 2023-09-14 University Of Rochester Cyclopeptibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4867962A (en) * 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
GB8915414D0 (en) * 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
AU6909191A (en) * 1989-11-20 1991-06-13 Parker, David L. Improved cd-30 antibodies and fragments thereof
WO1992000762A1 (en) * 1990-07-05 1992-01-23 Akzo N.V. Receptor directed-toxin conjugates
DE4200043A1 (de) * 1991-11-11 1993-05-13 Stein Harald Prof Dr Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren
ES2252732T3 (es) * 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
US5541287A (en) * 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds

Also Published As

Publication number Publication date
US5753203A (en) 1998-05-19
US20090264349A1 (en) 2009-10-22
WO1993024135A1 (en) 1993-12-09
US5480981A (en) 1996-01-02
ATE311895T1 (de) 2005-12-15
US5677430A (en) 1997-10-14
NO942851L (no) 1994-08-01
AU4389593A (en) 1993-12-30
AU666388B2 (en) 1996-02-08
EP0615451A4 (en) 1997-04-23
DE69334070T2 (de) 2007-01-04
AU685702B2 (en) 1998-01-22
US7232660B2 (en) 2007-06-19
ES2252732T3 (es) 2006-05-16
US6143869A (en) 2000-11-07
CA2131003A1 (en) 1993-12-09
DK0615451T3 (da) 2006-04-24
DE69334070D1 (de) 2006-11-16
EP0615451A1 (en) 1994-09-21
US20040241758A1 (en) 2004-12-02
US6667039B1 (en) 2003-12-23
EP0615451B1 (en) 2005-12-07
AU5198696A (en) 1996-08-01

Similar Documents

Publication Publication Date Title
NO942851D0 (es)
DE69334111D1 (en) Cd27 ligand
CA2312667A1 (en) Novel cytokine
EP0696206A4 (en) ADENOVIRUSES CONTAINING MODIFIED FIBROUS PROTEINS
AU8635391A (en) Nucleotide sequences coding for a human protein with angiogenesis regulative properties
KR100271382B1 (en) Human receptor h4-1bb
EP1007537A4 (en) RECEPTOR PROTEIN DESIGNATED BY 2F1
CA2223433A1 (en) Ob protein compositions and methods
EP0871726A4 (en) MULTI-SPECIFIC CHIMER RECEPTORS
CA2195557A1 (en) Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
EP0804482A4 (en) CYTOKINES BINDING THE HEK CELL SURFACE RECEPTOR
AU3728193A (en) (in vitro) activation of cytotoxic T cells
CA2122714A1 (en) Materials comprising and methods of preparation and use for ribosome-inactivating proteins
IL96907A0 (en) Proteins produced by human lymphocytes,a dna sequence coding for said proteins and their pharmaceutical and biological application
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
Farace et al. The decreased expression of CD3 ζ chains in cancer patients is not reversed by IL‐2 administration
WO1994028132A3 (en) Opioid receptors: compositions and methods
NZ332829A (en) Use of a polypeptide corresponding to a serine threonine kinase receptor, ALK-7 for neurological diseases
CA2175476A1 (en) Opioid receptor: compositions and methods
DE69837915D1 (de) Zusammensetzung aus liganden/lytischen petiden und ihre verwendung
CA2095335A1 (en) Cell growth inhibitors
NZ320932A (en) Short forms of chemokine b-8
Gordon et al. A human b-cell lymphoma synthesizing and expressing surface mu-chain in the absence of detectable light chain
EP0662150A4 (en) MASPIN, NEW SERPIN WITH ANTI-TUMOR ACTIVITY.
CA2139430A1 (fr) Polypeptides ayant une activite de recepteur serotoninergique (5ht5a), acides nucleiques codant pour ces polypeptides et utilisations